Fat cells allow melanoma cells to penetrate the dermis, from which they spread, causing fatal metastases in vital organs, TAU researchers say
Researchers at Tel Aviv University, led by Prof. Carmit Levy and Dr. Tamar Golan of the Department of Human Genetics and Biochemistry at TAU’s Sackler School of Medicine, have discovered that fat cells are involved in the transformation that melanoma cells undergo from cancer cells of limited growth in the epidermis to lethal metastatic cells attacking patients’ vital organs.
“We have answered a major question that has preoccupied scientists for years,” explains Prof. Levy. “What makes melanoma change form, turning aggressive and violent? Locked in the skin’s outer layer, the epidermis, melanoma is very treatable; it is still Stage 1, it has not penetrated the dermis to spread through blood vessels to other parts of the body and it can simply be removed without further damage.
“Melanoma turns fatal when it ‘wakes up,’ sending cancer cells to the dermis layer of skin, below the epidermis, and metastasizing in vital organs. Blocking the transformation of melanoma is one of the primary targets of cancer research today, and we now know fat cells are involved in this change.””
The research was conducted in collaboration with several senior pathologists: Dr. Hanan Vaknin of Wolfson Medical Center, and Dr. Dov Hershkowitz and Dr. Valentina Zemer of Tel Aviv Medical Center.
The study was on published July 23 in Science Signaling and is featured on the journal’s cover.
In the study, the researchers examined dozens of biopsy samples taken from melanoma patients at Wolfson Medical Center and Tel Aviv Medical Center, and observed a suspicious phenomenon: fat cells near the tumor sites.
“We asked ourselves what fat cells were doing there and began to investigate,” adds Prof. Levy. “We placed the fat cells on a petri dish near melanoma cells and followed the interactions between them.”
The researchers observed fat cells transferring proteins called cytokines, which affect gene expression, to the melanoma cells.
“Our experiments have shown that the main effect of cytokines is to reduce the expression of a gene called miRNA211, which inhibits the expression of a melanoma receptor of TGF beta, a protein that is always present in the skin,” says Prof. Levy. “The tumor absorbs a high concentration of TGF beta, which stimulates melanoma cells and renders them aggressive.”
Critically, the researchers have also found a way to block this transformation.
“It is important to note that we found the process reversible in the laboratory: When we removed the fat cells from the melanoma, the cancer cells calmed down and stopped migrating,” adds Prof. Levy.
A trial of mouse models of melanoma yielded similar results: When miRNA211 was repressed, metastases were found in other organs, while re-expressing the gene blocked metastases formation.
In the search for a potential drug based on the new discovery, the researchers experimented with therapies that are known to inhibit cytokines and TGF beta, but which have never before been used to treat melanoma.
“We are talking about substances that are currently being studied as possible treatments for pancreatic cancer, and are also in clinical trials for prostate, breast, ovarian and bladder cancers,” Dr. Golan said. “We saw that they restrained the metastatic process, and that the melanoma returned to its relatively ‘calm’ and dormant state.”
“Our findings can serve as a basis for the development of new drugs to halt the spread of melanoma — therapies that already exist, but were never used for this purpose,” concludes Prof. Levy. “In the future, we are seeking to collaborate with drug companies to enhance the development of the metastatic melanoma prevention approach.”
The Latest on: Melanoma
via Google News
The Latest on: Melanoma
- Iovance Stock Down on Delay in Filing for Melanoma Candidateon October 7, 2020 at 8:32 am
Shares of Iovance Biotherapeutics, Inc. IOVA fell about 12.4% after it announced that it will delay its biologics license application (BLA) submission to the FDA for its tumor-infiltrating lymphocyte ...
- Risk of melanoma may be gauged long before suspicious moles appear – studyon October 7, 2020 at 6:02 am
Research suggests genomic methods used to probe skin damage could be developed to estimate baseline risk of the skin cancer.
- Iovance stock drops nearly 10% following snag with FDA over experimental melanoma treatmenton October 6, 2020 at 11:22 am
Shares of Iovance Biotherapeutics, which is building a commercial manufacturing and office complex at the Philadelphia Navy Yard, were down 10% Tuesday on news about its experimental melanoma ...
- Iovance's stock tumbles over questions about regulatory submission for melanoma drugon October 6, 2020 at 5:08 am
Shares of Iovance Biotherapeutics Inc. were down 20.0% in premarket trading on Tuesday, the day after the biotechnology company said it plans to now submit an application to the Food and Drug ...
- Iovance Biotherapeutics Provides Update for Lifileucel in Metastatic Melanomaon October 5, 2020 at 1:01 pm
(GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today provided a regulatory update for its ...
- Bristol Myers Opdivo + Yervoy again shows underwhelming response in melanoma studyon October 5, 2020 at 4:50 am
Bristol (NYSE:BMY) announces results for the co-primary endpoint for CheckMate-915, a randomized Phase 3 study evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus Opdivo for patients ...
- Ultimovacs Announces Positive Topline Results from Phase I Combination Trial Evaluating Universal Cancer Vaccine, UV1, in Malignant Melanoma Patientson September 30, 2020 at 8:27 am
Ultimovacs ASA ("Ultimovacs", ticker ULTIMO), today announced positive topline results from the first cohort of 20 patients in its ongoing US-based Phase I clinical trial evaluating the Company’s lead ...
- Melanoma Detection Market 2020 : Top Countries Data with Market Size, Share, Growth Analysis, Industry basis of Region to 2026on September 30, 2020 at 2:18 am
Melanoma Detection Market"Research Report 2020-2026 provides key analysis on the market status of the Melanoma ...
- Surgeon general’s disclosure puts spotlight on melanomaon September 29, 2020 at 9:16 am
According to the U.S. Centers for Disease Control and Prevention, the incidences of melanoma has doubled during the past three decades and just recently U.S. Surgeon General Jerome Adams acknowledged ...
- Melanoma Drugs Market 2020 is Evolving Rapidly with Economic Growth, Demand Analysis, Geographical Segmentation and Forthcoming Opportunitieson September 28, 2020 at 8:46 pm
The Global Melanoma Drugs Market 2020 Global Industry Size, Share, Forecasts Analysis, Company Profiles, Competitive Landscape and Key Regions 2026 Analysis, Latest Innovations, Impacting Factors, ...
via Bing News